About Us
Discoveries in science and technology mean our knowledge of diseases has grown to the point where more people live healthier lives than ever before. This is progress but more needs to be done, especially for those living with unmet medical needs. At Dompé, we push our understanding of science and pursue research and development in new and unexpected areas to positively impact those patients’ lives.
People across the globe
M
Revenues in euro (2024)
M
Packages manufactured in 2020
Production lines (7 synthesis, 1 biotech)
Therapeutic Areas
Ophthalmology, Neurology and Pain
Reach
Europe, United States, China
CDMO
Synthesis and biotech
Biotech Approvals
AIFA (National Medicines Agency), Italy
EMA (European Medicines Agency), Europe
FDA (Food and Drug Administration), USA
NMPA (National Medical Products Administration), China
Health Canada
Ministry of Health of the Russian Federation
GLP (Good Laboratory Practices) Certificate of Compliance
EMA (European Medicines Agency), Europe
FDA (Food and Drug Administration), USA
NMPA (National Medical Products Administration), China
Health Canada
Ministry of Health of the Russian Federation
GLP (Good Laboratory Practices) Certificate of Compliance
Dompé U.S. Inc. is part of the Dompé farmaceutici S.p.A., parent company of the Dompé operating companies, with headquarters in Milan, Italy. We are an international biopharmaceutical company active across the entire pharmaceutical value chain, from research to development, production and commercialization. Our journey began as Milan’s first compounding pharmacy and has grown into a global organization. As a long-established family company, we blend the stability of our 130-year heritage with the agility and dynamism of a biotech start-up.
Innovative research leads to novel treatments
In the pursuit of improving human health, our R&D strives to break through in unconventional places. This is what led us to Nerve Growth Factor (NGF), a Nobel Prize-winning discovery made in 1986. We leveraged 50 years of research to transform this breakthrough into the first approved treatment for a rare degenerative eye disease. That deep appreciation of science continues to drive our investigation of neurotrophins.
Harnessing technology to accelerate drug discovery
Our relentless pursuit of new treatments for disease has led us to harness the potential of bioinformatics to accelerate the drug discovery process. The result is Exscalate, a structure-based virtual screening platform developed in-house and presently one of the most powerful supercomputing and artificial intelligence platforms for drug testing. It is the most extensive enumerated chemical library in the world for preclinical and clinical candidate identification.
Our production hub is the heart of Dompé
We can turn transformative breakthroughs into treatments because we have the right qualities and capabilities to deliver new drugs. Our 170,000 square meter R&D and production site in L’Aquila, Italy, is the heart of Dompé. Here, we conduct vital research, and produce and distribute our Primary Care and Biotech products.
We value our people
Our people are our most important asset. Our passion for making a meaningful difference in patients’ lives drives us for word. In the relentless pursuit of our mission, we adhere scrupulously to ethical principles, operate with the highest integrity, and ensure that we listen and learn from patients. We are also deeply committed to partnering with the scientific community to unlock the full potential of drug and technology innovation and advance discoveries into transformative treatments.
Focused on the road ahead
Our hunger to keep progressing, and to deliver what patients need from science, keeps us focused on what matters. We are embracing the challenge to transform our science and ourselves.